Long-Acting Cabotegravir for HIV Prevention
Joshua M. Sharfstein, Amy Killelea, Derek T. Dangerfield
Abstract
This Viewpoint discusses the recent FDA approval of cabotegravir, the first injectable medication to help prevent HIV infection, and how its effectiveness may be complicated by the cost and complexity of the US health care system.
Topics & Concepts
MedicineHuman immunodeficiency virus (HIV)Intensive care medicineVirologyHIV/AIDS Research and InterventionsHIV Research and TreatmentHIV, Drug Use, Sexual Risk